Opio, a groundbreaking healthcare technology company, announced today that the National Institutes of Health (NIH) has awarded the company Fast Track funding for their innovative opioid treatment program. The funding will expand the reach of Opio’s revolutionary technology-driven solution to rural and underserved areas, addressing an urgent need to improve opioid treatment access and quality of care.

Founded by Amber Norbeck and Mike Pokorny, Opio’s mission is to transform the opioid treatment landscape by developing technology-driven solutions that enhance treatment efficiency, safety, and accessibility. The company’s signature technology, ZING^R, the first-ever robotic dose assembly system, has been specifically designed to improve the assembly of opioid treatment medication, focusing on precision, accuracy, and patient safety.

“We are honored to receive this Fast Track funding from NIH, which will allow us to reach more patients and have a significant impact on addressing the challenges of opioid treatment access, quality, and safety,” said Amber Norbeck, CEO and co-founder of Opio.

The Fast Track funding represents a critical investment in Opio’s ongoing efforts to improve opioid treatment in the United States, emphasizing rural and underserved areas where treatment access is limited or nonexistent.

“Expanding our technology-driven solution to these underserved areas will provide patients with high-quality care and help to reduce the overall burden of the opioid epidemic,” added Mike Pokorny, co-founder of Opio.

Opio’s innovative technology delivers a safe and reliable medication dose assembly process, eliminating the need for manual assembly and reducing medication errors, which can lead to complications and negative healthcare outcomes. Moreover, the robotic dose assembly system streamlines medication assembly and distribution, freeing up healthcare providers’ time and making the process more efficient. Opio’s technology can potentially transform the opioid treatment landscape by providing much-needed convenience, efficiency, and safety in medication preparation.

Opio’s receipt of Fast Track funding from NIH is a testament to the company’s impactful work in developing technology-driven solutions that prioritize patient outcomes. Their efforts to transform opioid treatment access, efficiency, and safety are critical in light of the ongoing opioid epidemic, which has disproportionately affected rural and underserved areas.

Opio’s team looks forward to working closely with NIH, healthcare providers, and all stakeholders to continue expanding their reach and impact, addressing the urgent need for improved access to opioid treatment programs.